Copper Peptides Injections for Skin: What the Evidence Shows

GHK is a tripeptide (glycyl-histidyl-lysine) that occurs naturally in human plasma and binds copper tightly; the copper complex is GHK-Cu. Since its discovery in 1973 it has become a common ingredient in skin and hair products.

The figure most often repeated in marketing comes from a 2018 review by Pickart and Margolina: plasma GHK is about 200 ng/mL at age 20 and falls to about 80 ng/mL by age 60. That decline is real data, but it does not establish that injecting GHK-Cu restores anything. A falling level is a correlation with age, not evidence that topping it up reverses skin ageing.

It is worth knowing who wrote that review. Both authors list their affiliation as R&D Skin Biology, a company in the GHK-Cu skin-care business, although the paper declares no conflict of interest. The review is a useful map of the literature, but it is not an independent assessment of it.

The human skin results that give GHK-Cu its reputation are from creams. The review summarises them as follows:

The only injection data in the review are rat studies, and they measured behaviour, not skin. Nothing in it tests an injected GHK-Cu product on human skin. Our separate GHK-Cu dosage guide reviewed the trial registry and found a facial device study and a patch study, but no registered trial of an injected preparation. A cream and an injection are different exposures: different tissue concentrations, different distribution, different risks. Results from one do not carry over to the other.

GHK-Cu is not an approved medicine for any indication in any market. Injectable GHK-Cu comes from two places: compounding pharmacies and research-chemical sellers.

FDA's list of bulk substances that may present significant safety risks in compounding includes an entry for GHK-Cu (for injectable routes of administration). FDA's stated concern is that compounded injectable GHK-Cu "may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities" and that there are limited data in humans to inform safety. The entry sits in the section of substances that were nominated for compounding and then withdrawn by the nominators.

Note the scope: the entry is specific to injection. Topical copper peptide in a cosmetic is a different regulatory category and a different exposure. If you are looking at injectable GHK-Cu, the GHK-Cu dosage page explains the vial arithmetic and why it rests on no established human dose. The arithmetic itself is the standard one: units = mg ÷ (vial mg ÷ mL water) × 100 on a U-100 syringe, which the mg to mL converter runs for any vial. Exact arithmetic does not fix an unsupported target.

Collagen peptides are hydrolysed collagen: animal collagen broken into fragments so they dissolve in water and can be absorbed from the gut. They are oral supplements, taken as powder in gram amounts. The skin trials behind them gave daily oral doses, mostly between 2.5 g and 10 g, for weeks to months. None of that involves a needle, and the details are in our collagen peptides guide.

So what is being sold as injectable collagen peptides? It generally falls into one of these:

• Dermal fillers. FDA regulates fillers as medical device implants, approved for creating a smoother or fuller appearance in specific facial areas and the backs of the hands. FDA notes that some fillers contain collagen. A filler is a structural implant, not a peptide signal.
• Mesotherapy or "skin booster" cocktails marketed with collagen, peptides or vitamins. They are not what the filler approvals cover, and the peptides in them are not approved drugs for skin.
• Oral collagen mislabelled by search habit: people type "injection" meaning "supplement".

Injecting a collagen hydrolysate meant for drinking is not a stronger version of the supplement. It is an unstudied use of a product made to food-grade, not sterile-injectable, standards.

"Injectable peptides for skin" is a marketing category, not a regulatory one. The table sorts what is sold under it by what it is and what backs it.

The topical side is where peptide skin research actually lives. A 2009 review by Gorouhi and Maibach of topical peptides for aged skin sorted them into four groups: signal peptides, enzyme-inhibitor peptides, neurotransmitter-inhibitor peptides and carrier peptides. That is a framework for creams. The injectable market borrows its vocabulary without its evidence.

No peptide injection is FDA-approved for skin tightening, wrinkles or collagen building. So there is no evidence-based "best" injectable peptide for skin tightening; there is only a ranking of how much evidence exists, by route:

1. Approved, controlled evidence: FDA-approved dermal fillers, for the areas they are approved for, given by a trained provider. These are devices, not peptides.
2. Controlled topical evidence: GHK-Cu creams (12-week studies, including one against placebo) and oral collagen peptides (randomised trials at gram doses). Modest, measured effects, many from industry-linked studies.
3. No controlled human evidence: injected GHK-Cu, injected "collagen peptides", peptide skin-booster cocktails.

FDA's guidance on fillers is a useful benchmark for the rest: do not inject yourself with dermal fillers, and do not buy filler products online because they could be counterfeit or not approved for use in the US. If that caution applies to approved devices, it applies at least as strongly to unapproved peptide vials.

Related compounds marketed for skin, such as AHK-Cu and Matrixyl, have their own pages with the same evidence-first framing.

A few questions sort a clinic or product quickly:

• Is it an approved product? For skin, the approved injectables are filler devices. If the answer is a peptide, it is not approved for skin.
• Who made it? A named 503A compounding pharmacy or 503B outsourcing facility, or a research seller labelling it not for human use?
• What is the evidence for this route? Ask for an injection study, not a cream study.
• What happens if it reacts? FDA's specific concern with injectable GHK-Cu is immunogenicity.

Technique, sites and rotation for any subcutaneous injection are covered in peptide injection sites. None of this is a recommendation to inject; for skin concerns, a dermatologist can tell you which approved options fit.